Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.6/5
Alphamab Co Ltd (9966 HK)
Watchlist
Contact IR
120
Analysis
Health Care
•
China
Alphamab Oncology produces and sells drugs. The Company manufactures and sells tumor immunobiology macromolecular targeted drug and other products. Alphamab Oncology provides services worldwide.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
28 Jul 2025 00:53
What Happens to China Healthcare? - The Soaring Shares, the Turning Point, and the Top Picks
Hengrui has entered into agreements with GSK for HRS-9821 and up to 11 programs, with high upfront payment of US$500 million and total amount of...
Xinyao (Criss) Wang
Follow
417 Views
Share
bullish
•
Nanjing Leads Biolabs
•
25 Jul 2025 01:07
Pre-IPO Nanjing Leads Biolabs (PHIP Updates) - Thoughts on the Valuation and the Outlook
Leads Biolabs’ IPO debut benefit from the current bull market sentiment for innovative drugs in HK market.But the reduction of holdings by early...
Xinyao (Criss) Wang
Follow
611 Views
Share
bullish
•
Quantitative Analysis
•
20 Jul 2025 02:05
HK Connect Flows Weekly (Jul 18th): Meituan, CCB, Alibaba, Ping An Insurance, Akeso, Tencent, Xiaomi
We analyzed the Hong Kong Connect Scheme for last week and highlighted flows for Meituan, CCB, Alibaba, Ping An Insurance, Akeso, Tencent, Xiaomi,...
Ke Yan, CFA, FRM
Follow
611 Views
Share
bullish
•
Ascentage Pharma Group Corp
•
16 Jul 2025 00:55
Ascentage Pharma (6855.HK) Placement - Thoughts on The Placing Price and the Outlook
The Placing price of HK$68.6 has priced in successful licensing deal of APG-2575. US$1.5-2.375bn is a more reasonable valuation. Biotech sector...
Xinyao (Criss) Wang
Follow
334 Views
Share
bullish
•
China Medical System
•
30 Jun 2025 00:55
Pre-IPO China Medical System (867 HK) - About the IPO in Singapore and Concerns on Valuation Outlook
Listing in SGX opens a new chapter and CMS is undergoing pipeline adjustments and strategic transformation. But as valuation logic changes, license...
Xinyao (Criss) Wang
Follow
352 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.4
x